Travere (TVTX) Surges 11.6%: Is This an Indication of Further Gains?

Travere Therapeutics (TVTX) shares soared 11.6% in the last trading session to close at $15.23. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 37.5% gain over the past four weeks. Last month, the FDA granted full approval to the company's marketed product, Filspari (sparsentan), an oral non-immunosuppressive drug, for treating primary IgA nephropathy (IgAN) in adults who stand at high/low risk of disease progression. The approva ...